Decreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Antibiotic-associated diarrhea due to Clostridium difficile (CDAD) is thought to reflect colonization of a disrupted microbial community by the pathogen. We profiled the fecal microbiota of patients with CDAD (both initial and recurrent episodes) by culture-independent phylogenetic analysis of 16S rRNA-encoding gene sequences. Compared with those from control subjects and patients with an initial episode, the fecal communities in patients with recurrent CDAD were highly variable in bacterial composition and were characterized by markedly decreased diversity. Preservation and restoration of the microbial diversity could represent novel strategies for prevention and treatment of recurrent CDAD, which is often recalcitrant to existing therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conversely, a small, open label pilot study comparing upper and lower GI routes of administration did not show any differences44”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [44]
In the citing paper
“The human gut microbiota can restrict the growth of pathogens to prevent them from colonizing the intestine (‘colonization resistance’).”
From Role of the gut microbiota in nutrient competition and protection against intestinal pathogen colonization (2023) · cites this paper as [28]
In the citing paper
“Gut microbiota with high diversity have higher colonization resistance than gut microbiota with low diversity as a result of antibiotic treatment [28].”
From Role of the gut microbiota in nutrient competition and protection against intestinal pathogen colonization (2023) · cites this paper as [28]
Citations
Cites
Measuring biological diversity
(2004) · Choice Reviews Online · doi:10.5860/choice.42-1547 · Cited by 6,621
Ecological and Evolutionary Forces Shaping Microbial Diversity in the Human Intestine
Ley, R. E., Peterson, D. A., & Gordon, J. I. (2006) · Cell · doi:10.1016/j.cell.2006.02.017 · Cited by 3,358 · cited 3×
“exist in a complex symbiosis with their host [5].”
BackgroundInfluentialSchloss, P. D., & Handelsman, J. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.3.1501-1506.2005 · Cited by 2,501 · cited 1×
“The distance matrix was fed into DOTUR [8] to group the sequences into operational taxonomic units (OTUs), calculate ecological diversity measures (including the Shannon index [9]), and generate rarefaction curves by use of an OTU definition of 97% sequence similarity.”
MethodAntibiotic-Associated Diarrhea
Bartlett, J. G. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp011603 · Cited by 1,197 · cited 1×
“Diarrhea is a common side effect of the administration of antibiotics, with Clostridium difficile being responsible for most of the severe cases of antibiotic-associated diarrhea (AAD), including the development of pseudomembranous colitis [1].”
BackgroundMcFarland, L. V. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00465.x · Cited by 872 · cited 1×
“difficile antibiotics or the administration of probiotic organisms— have been tried for treatment of RCD [12, 13] [14].”
BackgroundKyne, L., Warny, M., Qamar, A., & Kelly, C. P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03592-3 · Cited by 804 · cited 1×
“difficile toxin [11].”
Breaking The Cycle: Treatment Strategies for 163 Cases of Recurrent Clostridium Difficile Disease
McFarland, L. V., Elmer, G. W., & Surawicz, C. M. (2002) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05839.x · Cited by 724 · cited 1×
“difficile antibiotics or the administration of probiotic organisms— have been tried for treatment of RCD [12, 13] [14].”
BackgroundAas, J., Gessert, C. E., & Bakken, J. S. (2003) · Clinical Infectious Diseases · doi:10.1086/367657 · Cited by 518 · cited 1×
“individuals to patients with RCD [4, 15]—is to alter the patient’s microbiome and to restore colonization resistance.”
BackgroundBACTERIOTHERAPY FOR CHRONIC RELAPSING CLOSTRIDIUM DIFFICILE DIARRHOEA IN SIX PATIENTS
Tvede, M., & Rask-Madsen, J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92749-9 · Cited by 491
Vollaard, E. J., & Clasener, H. A. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.3.409 · Cited by 478 · cited 1×
“microbiota is that of “colonization resistance” [10].”
Cited by
Items 301–400 of 999
Diarrhea After Kidney Transplantation
Aulagnon, F., Scemla, A., DeWolf, S., Legendre, C. M., & Zuber, J. (2014) · Transplantation · doi:10.1097/tp.0000000000000335 · Cited by 68
“In addition to these systemic effects, which go far beyond the scope of this review, an imbalance in commensal flora increases the risk of pathogenic microbes, the most concerning of which at present is Clostridium difficile (35).”
BackgroundEmanuelsson, F., Claesson, B. E. B., Ljungström, L., Tvede, M., & Ung, K.-A. (2014) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365548.2013.858181 · Cited by 68
Microbiome of HIV-infected people
Dubourg, G., Surénaud, M., Lévy, Y., Hüe, S., & Raoult, D. (2016) · Microbial Pathogenesis · doi:10.1016/j.micpath.2016.05.015 · Cited by 70
Fecal Microbiota Transplantation
Cheng, Y., & Fischer, M. (2023) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0043-1760865 · Cited by 76
Gastrointestinal Microbiota–Mediated Control of Enteric Pathogens
Yurist-Doutsch, S., Arrieta, M.-C., Vogt, S. L., & Finlay, B. B. (2014) · Annual Review of Genetics · doi:10.1146/annurev-genet-120213-092421 · Cited by 67
“difficile colonization of the gut and an overall reduction in microbiota diversity when compared with healthy subjects as well as with patients suffering an initial episode of the disease (15).”
BackgroundSubtle Microbiome Manipulation Using Probiotics Reduces Antibiotic-Associated Mortality in Fish
Schmidt, V. T., Marta Gómez-chiarri, G., Roy, C., Smith, K. F., & Amaral‐Zettler, L. (2017) · mSystems · doi:10.1128/msystems.00133-17 · Cited by 75
“Although our data corroborate previous research in mammalian models indicating that antibiotic administration increases downstream mortality (6, 8, 10), limitations of our data set prevent any determination of causal mechanism.”
Gonzales-Luna, A. J., Carlson, T. J., & Garey, K. W. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2223345 · Cited by 71
“Furthermore, patients with primary CDI often have a lower degree of dysbiosis when compared to patients with recurrent CDI, who appear more dysbiotic.(34,43,44) Specifically, those with recurrent disease appear to have a lower relative abundance of Firmicutes and Bacteroidetes as well as a lower alpha-diversity (i.”
BackgroundTargeting the type III secretion system to treat bacterial infections
Marshall, N. C., & Finlay, B. B. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.855199 · Cited by 75
“Therefore, unlike antibiotics, they would not affect the viability or growth of the members of the host microbiome, which play an increasingly recognized role in health and disease as well as pathogen colonization [7,8].”
BackgroundDoré, J., Simrén, M., Buttle, L., & Guarner, F. (2013) · United European Gastroenterology Journal · doi:10.1177/2050640613502477 · Cited by 65
“Recurrent CDI infection may occur as a result of impaired host-response and an alteration in the intestinal microbiome.(38,39) The hypothesis for gut microbiota transplantation is to re-establish a normal gut microbiota to act as a barrier against proliferation of C.”
BackgroundVemuri, R. C., Gundamaraju, R., Shinde, T., & Eri, R. (2017) · Beneficial Microbes · doi:10.3920/bm2016.0115 · Cited by 66
Alzheimer's disease and symbiotic microbiota: an evolutionary medicine perspective
Fox, M., Knorr, D. A., & Haptonstall, K. M. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14129 · Cited by 66
Protective Effects of Bifidobacterial Strains Against Toxigenic Clostridium difficile
Wei, Y., Yang, F., Wu, Q., Gao, J., Liu, W., Liu, C., Guo, X., Suwal, S., Kou, Y., Zhang, B., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00888 · Cited by 73
“The diversity of gut microbiota from patients who developed CDI after antibiotic treatment decreased compared with patients who did not develop CDI (Chang et al., 2008).”
BackgroundRussell, G. H., Kaplan, J. L., Youngster, I., Baril‐Dore, M., Schindelar, L., Hohmann, E., & Winter, H. S. (2014) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000283 · Cited by 64
“Accepted antibiotic therapies such as metronidazole and vancomycin further perturb the gut flora that may protect against colonization with C difficile, resulting in reduced gut microbial diversity, depletion of Bacteroidetes and Firmicutes, and increased prominence of Proteobacteria that may predispose patients to re…”
BackgroundHourigan, S. K., Chirumamilla, S. R., Ross, T. L., Golub, J. E., Rabizadeh, S., Saeed, S. A., Elson, C. O., Kelly, C. P., Carroll, K. C., Oliva‐Hemker, M. M., et al. (2013) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000435434.53871.36 · Cited by 64
Wieczorkiewicz, J. T., Lopansri, B. K., Cheknis, A. K., Osmolski, J. R., Hecht, D. W., Gerding, D. N., & Johnson, S. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01820-15 · Cited by 63
The Eukaryotic Microbiome: Origins and Implications for Fetal and Neonatal Life
Miller, W. B. (2016) · Frontiers in Pediatrics · doi:10.3389/fped.2016.00096 · Cited by 70
Kelbrick, M., Hesse, E., & Brien, S. O. (2023) · Microbiology · doi:10.1099/mic.0.001384 · Cited by 94
Chang, J. Y., Shin, S. M., Chun, J., Lee, J., & Seo, J. (2011) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e318227e518 · Cited by 62
Self-citationAtopobiumandFusobacteriumas novel candidates for sarcoidosis-associated microbiota
Zimmermann, A., Knecht, H., Häsler, R., Zissel, G., Gaede, K. I., Hofmann, S., Nebel, A., Müller–Quernheim, J., Schreiber, S., & Fischer, A. (2017) · European Respiratory Journal · doi:10.1183/13993003.00746-2016 · Cited by 68
Pollock, F. J., Lamb, J. B., van de Water, J. A. J. M., Smith, H. A., Schaffelke, B., Willis, B. L., & Bourne, D. G. (2019) · Royal Society Open Science · doi:10.1098/rsos.190355 · Cited by 65
Prevention of Clostridium difficile Infection With Probiotics
Evans, C. T., & Johnson, S. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ138 · Cited by 72
“The rarefaction curves (measure of bacterial diversity) of the patients with initial CDI episodes overlapped those of the controls, whereas the curves of the recurrent CDI patients were markedly different [2].”
Complementary Amplicon-Based Genomic Approaches for the Study of Fungal Communities in Humans
Heisel, T. J., Podgorski, H., Staley, C. M., Knights, D., Sadowsky, M. J., & Gale, C. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116705 · Cited by 67
“63 (Shannon indices) in healthy adults when comparing OTUs clustered at 97% identity [44,45,46] and at less than ~2.”
BackgroundEfficacy of LFF571 in a Hamster Model of Clostridium difficile Infection
Trzasko, A., Leeds, J. A., Præstgaard, J., LaMarche, M. J., & McKenney, D. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06355-11 · Cited by 62
“difficile infection in humans, including the recurrence stage following a course of antibiotic treatment (7, 27).”
BackgroundNecrotizing enterocolitis and preterm infant gut bacteria
Warner, B. B., & Tarr, P. I. (2016) · Seminars in Fetal and Neonatal Medicine · doi:10.1016/j.siny.2016.06.001 · Cited by 71
Dieterle, M. G., Rao, K. K., & Young, V. B. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13958 · Cited by 71
Self-citationSanders, N. L., Bollinger, R. R., Lee, R., Thomas, S., & Parker, W. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i34.5607 · Cited by 68
Deutscher, A. T., Burke, C., Darling, A. E., Riegler, M., Reynolds, O. L., & Chapman, T. A. (2018) · Microbiome · doi:10.1186/s40168-018-0463-y · Cited by 62
“A reduction in gut microbial diversity may lower microbial colonization resistance, thereby allowing pathogenic microorganisms to establish in the gut [79].”
BackgroundExposure to Arsenic Alters the Microbiome of Larval Zebrafish
Dahan, D., Jude, B. A., Lamendella, R., Keesing, F., & Perron, G. G. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01323 · Cited by 62
“While a decrease in evenness was associated with adverse health effects in premature infants with necrotizing enterocolitis (Chang et al., 2008; McMurtry, 2015), increases in taxa richness at low concentrations of arsenic were also observed in contaminated aquifers (Li et al.”
BackgroundGut Microbiota and Clostridium difficile: What We Know and the New Frontiers
Piccioni, A., Rosa, F., Manca, F., Pignataro, G., Zanza, C., Savioli, G., Covino, M., Ojetti, V., Gasbarrini, A., Franceschi, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113323 · Cited by 70
Antibiotic treatments and microbes in the gut
Macfarlane, S. (2014) · Environmental Microbiology · doi:10.1111/1462-2920.12399 · Cited by 66
“…infection, usually vancomycin and metronidazole, may also lead to further modifications of the gut microbiota, recurrent C. difficile infections (Chang et al., 2008) and the increase in resistant strains, including vancomycin-resistant enterococci, which are an increasing problem in…”
InfluentialChemoprevention in Gastrointestinal Physiology and Disease. Natural products and microbiome
Greiner, A. K., Papineni, R. V. L., & Umar, S. (2014) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00044.2014 · Cited by 62
“It appears, for example, that a reduction in overall bacterial diversity is common in dysbiosis (22, 77, 86, 88).”
BackgroundPostbiotic-Enabled Targeting of the Host-Microbiota-Pathogen Interface: Hints of Antibiotic Decline?
Puccetti, M., Xiroudaki, S., Ricci, M., & Giovagnoli, S. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070624 · Cited by 62
Negative interactions determine Clostridioides difficile growth in synthetic human gut communities
Hromada, S. E., Qian, Y., Jacobson, T. B., Clark, R. L., Watson, L., Safdar, N., Amador‐Noguez, D., & Venturelli, O. S. (2021) · Molecular Systems Biology · doi:10.15252/msb.202110355 · Cited by 62
Role of Microbiota and Innate Immunity in RecurrentClostridium difficileInfection
Bibbò, S., Lopetuso, L. R., Ianiro, G., Rienzo, T. D., Gasbarrini, A., & Cammarota, G. (2014) · Journal of Immunology Research · doi:10.1155/2014/462740 · Cited by 71
“difficile multiplication and development, facilitated by dysbiosis, are necessary for CDAD [31, 32].”
BackgroundTranscriptional Profiling ofClostridium difficileand Caco‐2 Cells during Infection
Janvilisri, T., Scaria, J., & Chang, Y. (2010) · The Journal of Infectious Diseases · doi:10.1086/653484 · Cited by 64
Effect of fiber supplementation on the microbiota in critically ill patients
O’Keefe, S. J. (2011) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v2.i6.138 · Cited by 61
The Multifaceted Role of Commensal Microbiota in Homeostasis and Gastrointestinal Diseases
Silva, M. J. B., Carneiro, M. B. H., Pultz, B. D. A., Silva, D. P., Lopes, M. E., & dos Santos, L. M. (2015) · Journal of Immunology Research · doi:10.1155/2015/321241 · Cited by 70
“Additionally, Salmonella has the ability to change the process of phagocytosis [119, 120].”
BackgroundNorovirus in healthcare settings
Iturriza‐Gómara, M., & Lopman, B. A. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000094 · Cited by 57
“Other healthcare associated infections, such as Clostridium difficile diarrhea, are associated with altered microbiota composition characterized by a loss of diversity [68]; repopulation of the gut environment with ‘healthy’ microbiota can reverse chronic C.”
BackgroundProbiotics and Gastrointestinal Infections
Britton, R. A., & Versalovic, J. A. (2008) · Interdisciplinary Perspectives on Infectious Diseases · doi:10.1155/2008/290769 · Cited by 70
“Patients with recurrent CDAD had a marked decrease in the diversity of organisms in their fecal microbiota while patients that were free of recurrent disease had a normal microbiota [64].”
BackgroundPossible Association between Obesity and Clostridium difficile Infection
Leung, J., Burke, B., Ford, D., Garvin, G. M., Korn, C., Sulis, C., & Bhadelia, N. (2013) · Emerging infectious diseases · doi:10.3201/eid1911.130618 · Cited by 64
Perler, B. K., Chen, B., Phelps, E. L., Allegretti, J. R., Fischer, M., Ganapini, V., Krajicek, E. J., Kumar, V., Marcus, J., Nativ, L., et al. (2020) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001281 · Cited by 60
“The most common antibiotics used were amoxicillin (16), azithromycin (15), sulfamethoxazole/trimethoprim (10), and the most common indications were for urinary tract infections (31), pneumonia (16), and sinus infections (13).”
BackgroundTreatment ofClostridioides (Clostridium) difficileinfection
Oksi, J., Anttila, V.-J., & Eero, M. (2019) · Annals of Medicine · doi:10.1080/07853890.2019.1701703 · Cited by 70
Pradhan, B., Guha, D., Naik, A. K., Banerjee, A., Tambat, S., Chawla, S., Senapati, S., & Aich, P. (2018) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-018-9436-5 · Cited by 58
Massacci, F. R., Berri, M., Lemonnier, G., Guettier, E., Blanc, F., Jardet, D., Rossignol, M., Mercat, M.-J., Dore, J. M., Lepage, P., et al. (2020) · Animal Microbiome · doi:10.1186/s42523-020-0020-4 · Cited by 73
Recent insights into Clostridium difficile pathogenesis
Peniche, A. G., Savidge, T., & Dann, S. M. (2013) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000433318.82618.c6 · Cited by 70
Garneau, J. R., Valiquette, L., & Fortier, L. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-29 · Cited by 55
“Disruption of the normal intestinal microbiota is associated with a higher risk of CDI and antibiotics are generally the triggering factor [8-10].”
BackgroundRao, K. K., & Higgins, P. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000793 · Cited by 60
Clostridium Difficile Infection in Children: A Review
Borali, E., & Giacomo, C. D. (2016) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000001264 · Cited by 61
“Risk factors for RCDI in children have been described and include malignancy, recent hospitalisation, recent surgery, antibiotic use, number of antibiotic exposures by class, acid blocker use, immunosuppressant use, and hospitalacquired disease (15,69).”
InfluentialLung Microbiota and Its Impact on the Mucosal Immune Phenotype
Wu, B. G., & Segal, L. N. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.bad-0005-2016 · Cited by 61
“Observations have noted associations of specific microbes and the gut microbiome in obesity(5–8), coronary artery disease(9–12), Clostridium difficile colitis(13, 14), type 2 diabetes(15, 16), and inflammatory bowel disease(4, 17, 18).”
Fecal microbiota transplantation in children: a brief review
Hourigan, S. K., & Oliva‐Hemker, M. M. (2016) · Pediatric Research · doi:10.1038/pr.2016.48 · Cited by 56
“difficile with an increased risk of recurrent infection (8).”
Christofi, T., Panayidou, S., Dieronitou, I., Michael, C., & Apidianakis, Y. (2019) · Scientific Reports · doi:10.1038/s41598-019-51058-3 · Cited by 65
Boekhoud, I. M., Sidorov, I. A., Nooij, S., Harmanus, C., Sanders, I. M. J. G., Viprey, V. F., Spittal, W. D., Clark, E., Davies, K., Freeman, J., et al. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab097 · Cited by 56
Prebiotics, probiotics and digestive health
Balakrishnan, M., & Floch, M. H. (2012) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e328359684f · Cited by 53
“Antibiotic use creates a disturbed colonic microflora and leads to loss of colonization resistance and vulnerability to CDI and CDI recurrences [11].”
BackgroundAjami, N. J., Cope, J. L., Wong, M. C., Petrosino, J. F., & Chesnel, L. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02112-17 · Cited by 52
“Similarly, analysis of fecal microbiota composition from patients with CDI shows decreased microbially diverse populations in those with recurrent CDI versus in those presenting with an initial incident of recurrence (21).”
BackgroundWang, J., Xiong, K., Zhao, S., Zhang, C., Zhang, J., Xu, L., & Ma, A. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00053 · Cited by 65
Gut Dysbiosis and Clostridioides difficile Infection in Neonates and Adults
Vasilescu, I.-M., Chifiriuc, M. C., Pîrcălăbioru, G. G., Filip, R., Bolocan, A., Lazăr, V., Diţu, L.-M., & Bleoţu, C. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.651081 · Cited by 61
Ridinilazole: a novel therapy for Clostridium difficile infection
Vickers, R. J., Tillotson, G., Goldstein, E. J. C., Citron, D. M., Garey, K. W., & Wilcox, M. H. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.04.026 · Cited by 54
“In patients with recurrent CDI, there is decreased diversity in the intestinal microbiota compared with either non-CDI patients or cured CDI patients who did not experience a recurrence [88].”
BackgroundFecal Microbiota Transplantation for multidrug-resistant organism: Efficacy and Response prediction
Seong, H., Lee, S. K., Cheon, J. H., Yong, D., Koh, H., Kang, Y., Jeong, W. Y., Lee, W. J., Sohn, Y., Cho, Y., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.09.003 · Cited by 58
Fecal microbiota transplant in patients with Clostridium difficile infection: A systematic review
Chapman, B. C., Moore, H. B., Overbey, D. M., Morton, A. P., Harnke, B., Gerich, M. E., & Vogel, J. D. (2016) · Journal of Trauma and Acute Care Surgery · doi:10.1097/ta.0000000000001195 · Cited by 51
“Altered microbiota and decreased diversity of colonic microflora that normally limits expansion of C. difficile has been hypothesized to be a key factor in the development of CDI.40,41 Currently, standard treatment of CDI is antibiotic therapy; however, recurrence of infection occurs in 15% to 35% of patients within 3…”
BackgroundInfluentialFriedman-Korn, T., Livovsky, D. M., Maharshak, N., Cohen, N. A., Paz, K., Shitrit, A. B., Goldin, E., & Koslowsky, B. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4833-2 · Cited by 58
“The estimated efficacy of antibiotic therapy for a first recurrence is 60%, a proportion that further declines in patients with multiple recurrences [8, 9].”
Elie, C., Perret, M., Hage, H., Sentausa, E., Hesketh, A., Louis, K., Fritah, A., Leissner, P., Vachon, C., Rostaing, H., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-33959-6 · Cited by 63
Gut microbiota and the development of pediatric diseases
Lu, C., & Ni, Y. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-015-1082-z · Cited by 54
Newton, D. F., Macfarlane, S., & Macfarlane, G. T. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00079-13 · Cited by 64
Prevalence and Source of Fecal and Oral Bacteria on Infant, Child, and Adult Hands
Shaffer, M., & Lozupone, C. (2018) · mSystems · doi:10.1128/msystems.00192-17 · Cited by 54
Wu, Z., Xu, Q., Gu, S., Chen, Y., Lv, L., Zheng, B., Wang, Q., Wang, K., Wang, S., Xia, J., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.841920 · Cited by 57
Shukla, S. K., Ye, Z., Sandberg, S., Reyes, I., Fritsche, T. R., & Keifer, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183898 · Cited by 60
Pakpour, S., Bhanvadia, A., Zhu, R., Amarnani, A., Gibbons, S. M., Gurry, T., Alm, E. J., & Martello, L. A. (2017) · Microbiome · doi:10.1186/s40168-017-0368-1 · Cited by 49
“of patients with initial and recurrent CDI is noticeably lower than that of healthy subjects [23, 24].”
BackgroundPark, H., Laffin, M. R., Jovel, J., Millan, B., Hyun, J. E., Hotte, N., Kao, D., & Madsen, K. L. (2019) · Gut Microbes · doi:10.1080/19490976.2019.1586037 · Cited by 49
“Clinical studies have shown a progressive loss of microbial diversity in patients with rCDI that is directly related to the duration of antibiotic treatment.(31) Other studies have shown that sub-lethal concentrations of several different antibiotics can stimulate virulent bacteriophages.”
Backgroundden Abbeele, P. V., Verstraete, W., Aidy, S. E., Geirnaert, A., & de Wiele, T. V. (2013) · Microbial Biotechnology · doi:10.1111/1751-7915.12049 · Cited by 58
“This is also valid for the microbial ecosystem of the human gut where a decreased diversity has been correlated with disease states such as recurrent Clostridium difficile infection (Chang et al., 2008), Crohn's disease (Manichanh et al., 2006) and obesity (Turnbaugh et al., 2009).”
BackgroundFecal microbiota transplantation: current clinical efficacy and future prospects
Surawicz, C. M., Bowman, K. A., & Broussard, E. K. (2015) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s61305 · Cited by 54
“CDI patients have decreased overall microbiome diversity and less Bacteroidetes and Firmicutes than seen in healthy people.(2,3) Instead, CDI patients have high levels of Proteobacteria and Verrucomicrobia, which are frequently invasive pathobionts.”
Clostridium difficileinfection in children: a comprehensive review
Pant, C., Deshpande, A., Altaf, M. A., Minocha, A., & Sferra, T. J. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.803058 · Cited by 57
Therapeutic manipulation of the microbiota: past, present, and considerations for the future
Young, V. B. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.09.001 · Cited by 54
“difficile infection is also associated with reduced microbiota diversity [18] and several investigators have noted that successful fecal transplantation is associated with a corresponding increase in intestinal microbiome diversity [20, 21].”
BackgroundSelf-citationOutcomes With Fidaxomicin Therapy in Clostridium difficile Infection
Spiceland, C. M., Khanna, S., & Pardi, D. S. (2018) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000769 · Cited by 48
Host-parasite interactions under extreme climatic conditions
Martínez, J., & Merino, S. (2011) · Current Zoology · doi:10.1093/czoolo/57.3.390 · Cited by 62
“In addition, they are able to exert a protective role against certain diseases because the alteration of these microbial communities has been linked on several occasions to increased susceptibility to a disease (Holzman et al., 2001; Roos et al., 2001; Chang et al., 2008).”
BackgroundNew and emerging therapies for Clostridium difficile infection
Martin, J. S. H., & Wilcox, M. H. (2016) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000320 · Cited by 50
“Vaccination to boost host antibody-mediated immunity is a promising strategy to reduce CDI.”
BackgroundInfluentialWilcox, M. H., McGovern, B., & Hecht, G. A. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa114 · Cited by 51
“, dysbiosis).(8) Thus, antibiotics are a main driver of compositional and functional”
Frost, F., Kacprowski, T., Rühlemann, M. C., Weiß, S., Bang, C., Franke, A., Pietzner, M., Aghdassi, A. A., Sendler, M., Völker, U., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-86247-6 · Cited by 49
Stalenhoef, J. E., Terveer, E. M., Knetsch, C. W., Hof, P. V. ‘., Vlasveld, I. N., Keller, J. J., Visser, L. G., & Kuijper, E. J. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx047 · Cited by 47
“We suggest that diminished diversity appears not to play a role in MDR carriership as opposed to recurrent CDI [7].”
BackgroundInfluentialButton, J. E., Cosetta, C. M., Reens, A. L., Brooker, S. L., Rowan-Nash, A. D., Lavin, R., Saur, R., Zheng, S., Autran, C. A., Lee, M. L., et al. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.08.004 · Cited by 53
Contemporary Applications of Fecal Microbiota Transplantation to Treat Intestinal Diseases in Humans
Staley, C. M., Khoruts, A., & Sadowsky, M. J. (2017) · Archives of Medical Research · doi:10.1016/j.arcmed.2017.11.006 · Cited by 50
Massive metagenomic data analysis using abundance-based machine learning
Harris, Z. N., Dhungel, E., Mosior, M., & Ahn, T.-H. (2019) · Biology Direct · doi:10.1186/s13062-019-0242-0 · Cited by 50
Clostridioides difficile and Gut Microbiota: From Colonization to Infection and Treatment
Spigaglia, P. (2024) · Pathogens · doi:10.3390/pathogens13080646 · Cited by 60
“Profound alterations were found in patients with recurrent CDI who had received multiple antibiotic treatments [143].”
Background(2014) · PubMed Central · Cited by 45
Kim, J., Cho, Y., Seo, M.-R., Bae, M. H., Kim, B., Rho, M., & Pai, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-74090-0 · Cited by 48
Gal, A., Barko, P. C., Biggs, P. J., Gedye, K. R., Midwinter, A. C., Williams, D. A., Burchell, R. K., & Pazzi, P. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250344 · Cited by 55
HIV, Sexual Orientation, and Gut Microbiome Interactions
Tuddenham, S., Koay, W. L. A., & Sears, C. L. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06110-y · Cited by 49
Host Immune Responses to Clostridioides difficile: Toxins and Beyond
Nibbering, B., Gerding, D. N., Kuijper, E. J., Zwittink, R. D., & Smits, W. K. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.804949 · Cited by 63
Broecker, F., Klumpp, J., & Moelling, K. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13100 · Cited by 48
Microbiota-Based Therapies for Clostridium difficile and Antibiotic-Resistant Enteric Infections
Lewis, B. B., & Pamer, E. G. (2017) · Annual Review of Microbiology · doi:10.1146/annurev-micro-090816-093549 · Cited by 51
Cabral, D. J., Wurster, J. I., Flokas, M. E., Alevizakos, M., Zabat, M., Korry, B. J., Rowan, A. D., Sano, W. H., Andreatos, N., Ducharme, R. B., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11427-2 · Cited by 43
Kellingray, L., Gall, G. L., Defernez, M., Beales, I. L. P., Franslem-Elumogo, N., & Narbad, A. (2018) · Journal of Infection · doi:10.1016/j.jinf.2018.04.012 · Cited by 43
Hourigan, S. K., Ahn, M., Gibson, K. M., Pérez-Losada, M., Felix, G., Weidner, M., Leibowitz, I., Niederhuber, J. E., Sears, C. L., Crandall, K. A., et al. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz379 · Cited by 43
“Dysbiosis of the intestinal microbiota has been well described in those with recurrent CDI, with markedly decreased fecal bacterial diversity [12].”
BackgroundCharacterization of Gut Microbiome in Korean Patients with Metabolic Associated Fatty Liver Disease
Oh, J. H., Lee, J., Cho, M. S., Kim, H., Chun, J., Lee, J. H., Yoon, Y., & Kang, W. (2021) · Nutrients · doi:10.3390/nu13031013 · Cited by 47
“Decreased richness has been linked to obesity [23], as well as inflammatory bowel disease [24] and recurrent Clostridium difficile associated diarrhea [25].”
BackgroundThe Human Microbiome and Probiotics: Implications for Pediatrics
Versalovic, J. (2013) · Annals of Nutrition and Metabolism · doi:10.1159/000354899 · Cited by 43
Khan, F. U., Shang, Y., Chang, X., Kong, H., Zuberi, A., Fang, J. K., Liu, W., Peng, J., Zhang, X., Hu, M., et al. (2021) · Frontiers in Marine Science · doi:10.3389/fmars.2021.736338 · Cited by 45
Choi, H. K., Kim, K. H., Lee, S. H., & Lee, S. J. (2011) · Journal of Korean Medical Science · doi:10.3346/jkms.2011.26.7.859 · Cited by 40
“681 Clinical outcome Time to recovery, days Severe CDI Shock Acute kidney injury Duration of hospitalization, days (outpatient excluded) 4 (1-40) 9 (10.”
BackgroundClostridium difficile Infection
Gerding, D. N., & Young, V. B. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00245-9 · Cited by 45
Self-citationPredominance of Lactobacillus spp. Among Patients Who Do Not Acquire Multidrug-Resistant Organisms
Araos, R., Tai, A., Snyder, G. M., Blaser, M. J., & D’Agata, E. M. C. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw426 · Cited by 46
Bian, X., Garber, J. M., Cooper, K. K., Huynh, S., Jones, J. A., Mills, M. K., Rafala, D., Nasrin, D., Kotloff, K. L., Parker, C. T., et al. (2020) · mSphere · doi:10.1128/msphere.00735-19 · Cited by 49
“In this study, we demonstrate that infants with diarrhea had the lowest fecal microbial diversity, consistent with data from previous studies that showed that diarrheal disease decreases the diversity of the gut microbiome (51).”
ResultMinority report: the intestinal mycobiota in systemic infections
Rolling, T., Hohl, T. M., & Zhai, B. (2020) · Current Opinion in Microbiology · doi:10.1016/j.mib.2020.05.004 · Cited by 47
“Similarly, in a study comparing fidaxomicin to vancomycin for CDI, Candida intestinal colonization was more frequently observed in the vancomycin arm [39], since fidaxomicin and not vancomycin was known to spare Bacteroides [40].”
BackgroundInfluential
Metadata
- Authors
- Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B.
- Affiliations
- Michigan State University (US)
- Corresponding author
- Young, Vincent B.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-02
- Volume
- 197
- Issue
- 3
- Pages
- 435-438
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2139607253
- Cited by
- 1,010
- References
- 15
- Citations by year
- 2026: 15 · 2025: 28 · 2024: 36 · 2023: 54 · 2022: 42 · 2021: 57 · 2020: 69 · 2019: 59 · 2018: 107 · 2017: 78 · 2016: 77 · 2015: 88 · 2014: 87 · 2013: 78 · 2012: 53
- FWCI
- 17.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
- Keywords
- Clostridium difficile, fecal microbiota, microbial diversity, antibiotic-associated diarrhea, 16S rRNA gene sequencing, bacterial community composition, dysbiosis, microbiota restoration
- MeSH terms
- Anti-Bacterial Agents, Diarrhea, Drug Administration Schedule, Enterocolitis, Pseudomembranous, Feces, Female, Humans, Male, Phylogeny, Recurrence, Reference Values, Genetic Variation, Clostridioides difficile
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.